

## Amy Schulman

Amy Schulman is a healthcare investor and Managing Partner at Polaris Partners. She also co-founded and acts as Managing Partner of the Polaris Innovation Fund, which was formed in 2017. Schulman currently serves as Executive Chair of SQZ Biotech, as well as Lyndra Therapeutics where she was a co-founder and the company's initial CEO. Amy joined Polaris in 2014.

Prior to joining Polaris, Schulman held various executive roles at Pfizer including as General Counsel, President of Pfizer Consumer Healthcare and Pfizer Nutrition, where she was instrumental in its sale to Nestle for \$11.85 billion.

Schulman has received numerous awards including 2019 PharmaVoice 100, Xconomy's 2017 Newcomer Award, Scientific American's 2015 Worldview 100 List, Fierce Biotech's 2014 Top 15 Women in Biotech, and Fortune Magazine's 2013 50 Most Powerful Women in Business. In addition to her Polaris boards, she serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) Mount Sinai Hospital, and Action Against Hunger, and served as a Senior Lecturer at Harvard Business School. She is also a Member of Singapore's Health and Biomedical Sciences International Advisory Council.

Schulman is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and English and earned her J.D. from Yale Law School.